文献速递免疫规划传染病防控与疫情报告

新型2型口服脊髓灰质炎疫苗病毒在紧急使用清单下初始使用阶段的基因特征——全球,2021年3月至10月

Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-06-17

对2021年3月至10月全球nOPV2基因组监测数据进行分析,通过全基因组测序检测急性弛缓性麻痹和环境监测分离株,确认主要减毒位点基因稳定,表明nOPV2相对于Sabin 2具有基因稳定性,并建议在EUL期间继续监测。

要点

  • 2021年3月至10月全球监测确认nOPV2主要减毒位点基因稳定。
  • 测序数据表明nOPV2相对于Sabin 2具有基因稳定性。
  • nOPV2监测应在紧急使用清单期间持续进行。

核心结论

  • 2021年3月至10月全球nOPV2基因组监测确认主要减毒位点基因稳定,序列数据表明nOPV2相对于Sabin 2具有基因稳定性,并提示nOPV2将成为脊髓灰质炎 eradication 的重要工具。

研究设计与样本

  • 基于紧急使用清单要求的监测框架,对急性弛缓性麻痹监测、环境监测、免疫后不良事件监测和特殊关注不良事件靶向监测中检测到的nOPV2分离株进行全基因组测序,数据由全球消灭脊髓灰质炎倡议nOPV工作组的基因特征亚组审查。

主要发现

  • 2021年3月至10月全球nOPV2基因组监测确认主要减毒位点基因稳定。
  • 测序数据表明nOPV2相对于Sabin 2具有基因稳定性。

关键数值与推荐

  • nOPV2监测应在紧急使用清单期间持续进行。

临床怎么用

  • nOPV2监测应在紧急使用清单期间持续进行。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence and international spread of neurovirulent circulating vaccine-derived polioviruses (cVDPVs) across multiple countries in Africa and Asia in recent years pose a major challenge to the goal of eradicating all forms of polioviruses. Approximately 90% of all cVDPV outbreaks are caused by the type 2 strain of the Sabin vaccine, an oral live, attenuated vaccine; cVDPV outbreaks typically occur in areas of persistently low immunization coverage (1). A novel type 2 oral poliovirus vaccine (nOPV2), produced by genetic modification of the type 2 Sabin vaccine virus genome (2), was developed and evaluated through phase I and phase II clinical trials during 2017-2019. nOPV2 was demonstrated to be safe and well-tolerated, have noninferior immunogenicity, and have superior genetic stability compared with Sabin monovalent type 2 (as measured by preservation of the primary attenuation site [domain V in the 5' noncoding region] and significantly lower neurovirulence of fecally shed vaccine virus in transgenic mice) (3-5). These findings indicate that nOPV2 could be an important tool in reducing the risk for generating vaccine-derived polioviruses (VDPVs) and the risk for vaccine-associated paralytic poliomyelitis cases. Based on the favorable preclinical and clinical data, and the public health emergency of international concern generated by ongoing endemic wild poliovirus transmission and cVDPV type 2 outbreaks, the World Health Organization authorized nOPV2 for use under the Emergency Use Listing (EUL) pathway in November 2020, allowing for its first use for outbreak response in March 2021 (6). As required by the EUL process, among other EUL obligations, an extensive plan was developed and deployed for obtaining and monitoring nOPV2 isolates detected during acute flaccid paralysis (AFP) surveillance, environmental surveillance, adverse events after immunization surveillance, and targeted surveillance for adverse events of special interest (i.e., prespecified events that have the potential to be causally associated with the vaccine product), during outbreak response, as well as through planned field studies. Under this monitoring framework, data generated from whole-genome sequencing of nOPV2 isolates, alongside other virologic data for isolates from AFP and environmental surveillance systems, are reviewed by the genetic characterization subgroup of an nOPV working group of the Global Polio Eradication Initiative. Global nOPV2 genomic surveillance during March-October 2021 confirmed genetic stability of the primary attenuating site. Sequence data generated through this unprecedented global effort confirm the genetic stability of nOPV2 relative to Sabin 2 and suggest that nOPV2 will be an important tool in the eradication of poliomyelitis. nOPV2 surveillance should continue for the duration of the EUL.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Martin J, Burns CC, Jorba J, et al. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35709073. doi:10.15585/mmwr.mm7124a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。